In mice, GLP-1/dexa reduced the expression of reward-related genes in the NAc such as D1R, dopamine receptor 2 long isoform (D2rlg), kappa opioid receptor (Kor), glucocorticoid receptor (Gr), others such as TH and dopamine transporter (DAT) were also decreased but non-significantly (Decarie-Spain et al., 2019)
One changes the metabolic engine
As these medications become among the most widely prescribed in the world, the ability to tailor treatment based on genetic profile or to target specific clinical outcomes such as cardiovascular risk reduction could transform prescribing practices well beyond their current primary use in obesity and diabetes management Sources New 23andMe Research Institute Study Identifies Genetic Predictors for GLP-1 Weight Loss Efficacy and Side Effects 23andME April 8, 2026 Genetic variations linked to weight loss, side effects from GLP-1 drugs Reuters April 10, 2026
A study published in the Journal of the American Medical Association demonstrated that individuals who drink one fructose-rich beverage a day are 74% more likely to develop gout than those who drink the same beverage once per month
